

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL

Large Infection Problems in Small Patients Merit a Renewed Emphasis on Prevention

NALINI SINGH, MD, MPH

714

ORIGINAL ARTICLES

Molecular Epidemiology of *Serratia marcescens* Outbreaks in Two Neonatal Intensive Care Units

VLADANA MILISAVLJEVIC, MD, MS; FANN WU, MD, PhD; ELAINE LARSON, PhD; DAVID RUBENSTEIN, MD; BARBARA ROSS, RN, CIC; LEWIS M. DRUSIN, MD, MPH; PHYLLIS DELLA-LATTA, PhD; LISA SAIMAN, MD, MPH

719

Clustering of *Serratia marcescens* Infections in a Neonatal Intensive Care Unit

EMMI SARVIKIVI, MD; OUTI LYYTIKÄINEN, MD, PhD; SAARA SALMENLINNA, MSc; JAANA VUOPIO-VARKILA, MD, PhD; PÄIVI LUUKKAINEN, MD, PhD; EVELIINA TARKKA, MSc; HARRI SAXÉN, MD, PhD

723

Rapid Eradication of a Cluster of *Serratia marcescens* in a Neonatal Intensive Care Unit: Use of Epidemiologic Chromosome Profiling by Pulsed-Field Gel Electrophoresis

KWAN KEW LAI, DMD, MD; STEPHEN P. BAKER, MSc, PH; SALLY A. FONTECCHIO, RN, BSNsgED, CIC

730

Antimicrobial Use and the Influence of Inadequate Empiric Antimicrobial Therapy on the Outcomes of Nosocomial Bloodstream Infections in a Neonatal Intensive Care Unit

ANUCHA APISARNTHANARAK, MD; GALIT HOLZMANN-PAZGAL, MD; AARON HAMVAS, MD; MARGARET A. OLSEN, PhD, MPH; VICTORIA J. FRASER, MD

735

Handwashing Program for the Prevention of Nosocomial Infections in a Neonatal Intensive Care Unit

SAU-PIN WON, MD; HUNG-CHIEH CHOU, MD; WU-SHIUN HSIEH, MD; CHIEN-YI CHEN, MD; SHIO-MIN HUANG, HN; KUO-INN TSOU, MD; PO-NIEN TSAO, MD, PhD

742

Survey of Knowledge, Beliefs, and Practices of Neonatal Intensive Care Unit Healthcare Workers Regarding Nosocomial Infections, Central Venous Catheter Care, and Hand Hygiene

ALLISON M. KENNEDY, MPH; ALEXIS M. ELWARD, MD; VICTORIA J. FRASER, MD

747

Ventilator-Associated Pneumonia in a Pediatric Intensive Care Unit in Saudi Arabia: A 30-Month Prospective Surveillance

MAHA ALMUNEEF, MD, FAAP, CIC; ZIAD A. MEMISH, MD, CIC, FRCPC, FACP, FIDSA; HANAN H. BALKHY, MD, CIC, FAAP; HALA ALALEM, MD; ABDULRAHMAN ABUTALEB, MD

753

Pattern of Culture-Proven Neonatal Sepsis in a District General Hospital in the United Kingdom

KHALID N. HAQUE, FRCP (LOND, EDIN, IRE), FRCPCH, FPAMS (PAK), FAAP, FICP, MBA, DCH, DTM&H; M. AJAZ KHAN, MBBS, MRCP; SALLY KERRY, MSc; JIM STEPHENSON, MBBS, MA, MSc, FRCPATH; GRETTA WOODS, BSc, RCN

759

Prevalence of Nosocomial Infections in Swiss Children's Hospitals

KATHRIN MÜHLEMANN, MD, PhD; CHRISTINE FRANZINI; CHRISTOPH AEBI, MD; CHRISTOPH BERGER, MD; DAVID NADAL, MD; JODY STÄHELIN, MD; HANSPETER GNEHM, MD; KLARA POSFAY-BARBE, MD; ALAIN GERVAIX, MD; HUGO SAX, MD; ULRICH HEININGER, MD; JAN BONHOEFFER, MD; GERHARD EICH, MD; CHRISTIAN KIND, MD; CHRISTIANE PETIGNAT, MD; PIETRO SCALFARO, MD


765

Healthcare-Associated Infections Among Neonates in Brazil


CARMEM LÚCIA PESSOA-SILVA, MD; ROSANA RICHTMANN, MD; ROSELI CALIL, MD; ROSANA MARIA RANGEL SANTOS, MD; MARIA LUIZA M. COSTA, RN; ANA CRISTINA CISNE FROTA, MD; SERGIO BARSANTI WEY, MD

772

Continued inside.



Kill.



**Keep
killing.**

**For immediate and persistent antiseptic activity,
you're in the clear with Hibistat® and Hibiclens®.**

Clinical studies* have proven the efficacy and persistence of Hibistat® and Hibiclens®, demonstrating both antiseptics go to work on germs in seconds, and have a cumulative effect that continues to kill germs long after your shift is over.

*In the most recent study, a novel demonstration was developed to prove their antiseptic persistence. The study consisted of using agar plates that were inoculated with staph aureus. Hands were either rinsed or washed with Hibistat® or Hibiclens®, and then pressed onto the inoculated plates – palms down. The plates were then incubated and a whitish film of staph aureus grew in areas **not** affected by antiseptic activity.*



Plates touched by Hibistat® showed immediate kill, displaying a clear, darker-colored handprint on areas affected by the antiseptic rinse. Hibistat®, with its alcohol + chlorhexidine gluconate (CHG) formulation, went to work on contact and showed persistence after only one hand rinse, making it an ideal, portable companion when regular handwashing is not an option.**

Hibiclens®, armed with its 4% Hibitane® (CHG) formulation, killed immediately and displayed a cumulative effect that didn't know when to quit. In fact, this demonstration showed the antiseptic still killing on the fifth day of use and 6 hours after the final daily hand wash.***



HIBISTAT®
Healthcare Personnel Hand Antiseptic

**Immediately kill and keep killing germs with Hibistat® and
Hibiclens®. For more information about Hibistat® or Hibiclens®,
call 1-800-843-8497.**

HIBICLENS®
Antiseptic / Antimicrobial Skin Cleanser

*Data on file.

**Left photo - The darker color in the handprint shows the immediate effect of Hibistat® on staph aureus.

***Right photo - The darker color in the hand print shows the cumulative effect of Hibiclens® on staph aureus the 5th day of use, 6 hours after the final daily hand wash.

The persistence of Hibistat® and Hibiclens® provides extra protection. Recommended antiseptic procedures of your institution should be followed when using either of these antiseptics.



Regent Medical

From the makers of Hibiclens® and Biogel®. www.regentmedical.com. Regent, Biogel, Hibiclens, Hibistat, Regent logo, Biogel logo, Hibiclens logo, and Hibistat logo are trade marks of Regent Medical, Ltd. Distributed by Regent Medical, Ltd., Norcross, GA 30092. ©2004 Regent Medical, Ltd. All rights reserved.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

CONTENTS

Continued from cover

ORIGINAL ARTICLE

Transmission of Methicillin-Resistant *Staphylococcus aureus* to Preterm Infants Through Breast Milk

PRIYA BEHARI, MD; JANET ENGLUND, MD; GRACE ALCASID, MPH, MT(ASCP); SYLVIA GARCIA-HOUCHINS, CIC; STEPHEN G. WEBER, MD, MSC

778

CONCISE COMMUNICATIONS

Risk Factors for Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in a Neonatal Intensive Care Unit

DARREN R. LINKIN, MD; NEIL O. FISHMAN, MD; JEAN BALDUS PATEL, PhD, (D)ABMM; JEFFREY D. MERRILL, MD; EBBING LAUTENBACH, MD, MPH, MSCE

781

Pediatric Risk of Mortality and Hospital Infection

AGLAI ARANTES, MD; EDUARDO DA SILVA CARVALHO, PhD; EDUARDO A. S. MEDEIROS, PhD; CALIL KAIRALLA FARHAT, PhD; ORLANDO CESAR MANTESE, PhD

783

Impact of Surveillance Rounds on Adherence to Infection Control Policies and Procedures at a Children's Hospital

ARCHANA CHATTERJEE, MD, PhD; BRENDA HEYBROCK, RN; SHARON PLUMMER, RN, CIC; KAY EISCHEN, RN, MS

786

Survey of Tuberculin Skin Test Positivity Among Israeli Pediatric Hospital Workers

YARON FINKELSTEIN, MD; HENIA ELENBERG, MA, RN; GABRIEL CHODICK, MSc, MHA; VERED HOFFER, MD; ITAMAR SHALIT, MD; BEN-ZION GARTY, MD

788

LETTERS TO THE EDITOR

Use of Pulsed-Field Gel Electrophoresis for a Pseudoepidemic of *Clostridium difficile* Infections in a Pediatric Oncology and Hematology Department

CELINE HERNANDEZ, MD; OLIVIER MEUNIER, MD, PhD; FREDERIQUE AUDEOUD, MD; PATRICK LUTZ, MD, PhD; MICHEL BIENTZ, MD, PhD

708

Infections Due to Group B Streptococci in Neonates Are Not Associated With Higher Mortality Than Infections Due to Other Organisms

B. M. HAFED, MD, PhD; E. BILIKOVA, PhD; J. KOPRNOVA, PhD; G. KOVACICOVA, PhD; I. SVETLANSKY, PhD; V. KRČMERY, PhD

709

MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD

792

Full-text articles available online at ICHEJournal.com

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0195-9417, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Road, Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 66 Canal Center Plaza, Suite 600, Alexandria, VA 22314; telephone, 703-299-0200; fax, 703-299-0204; e-mail address, info@shea-online.org.

COPYRIGHT 2004 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$139.00; Two years-\$199.00; Three years-\$259.00; Institutional: One year-\$269.00; Two years-\$459.00; Three years-\$639.00. Fellows: \$54.50 per year with proof of training status. Canada: add 7% Goods & Services tax; Overseas: add \$49.00 each year for delivery by air service. Single copies of current issues may be obtained for \$24.00.

INSTRUCTIONS TO AUTHORS: Authors may submit electronic versions of their manuscripts prepared in accordance with the 2001 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." An electronic version is available at www.icmje.org. Submit to RapidReview.com. All submissions must be accompanied by copyright form(s) signed by all authors.

REPRINTS: All requests to reprint or use material published herein should be addressed to John Kain, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086. For reprint orders and prices, contact Rebecca Fogarty at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.20 per page is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923; phone (978) 750-8400. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.

EDITORIAL OFFICE

SLACK Incorporated
6900 Grove Road
Thorofare, NJ 08086
(856) 848-1000; (856) 848-6091 (FAX)
E-mail: iche@slackinc.com

EDITOR

Barry M. Farr, MD, MSc

DEPUTY EDITORS

David P. Calfee, MD, MS

William R. Jarvis, MD

ASSISTANT EDITOR

Preeti N. Malani, MD, MSJ

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Infections in Immunocompromised**Patients**

Kent Sepkowitz, MD

New York City, New York

Information Management

John A. Sellick, DO

Amherst, New York

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL ADVISORY BOARD

- | | |
|---------------------------------|------------------------------------|
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Miriam Alter, PhD | Atlanta, Georgia |
| Hilary Babcock, MD | St. Louis, Missouri |
| Elise M. Beltrami, MD, MPH | Decatur, Georgia |
| Richard E. Besser, MD | Atlanta, Georgia |
| Marc J. M. Bonten, MD, PhD | Utrecht, The Netherlands |
| John M. Boyce, MD | New Haven, Connecticut |
| Christian Brun-Buisson, MD | Creteil, France |
| John P. Burke, MD | Salt Lake City, Utah |
| Yehuda Carmeli, MD, MPH | Tel Aviv, Israel |
| Carol Chenoweth, MD | Ann Arbor, Michigan |
| Sara E. Cosgrove, MD, MS | Baltimore, Maryland |
| Donald E. Craven, MD | Burlington, Massachusetts |
| Erika D'Agata, MD, MPH | Boston, Massachusetts |
| Franz Daschner, MD | Freiburg, Germany |
| Patch Dellinger, MD | Seattle, Washington |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Jean Yves Fagon, MD, MPH | Paris, France |
| Mark Farrington, MA, FRCPath | Cambridge, England, United Kingdom |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Petra Gastmeier, MD | Hanover, Germany |
| Dale N. Gerding, MD | Hines, Illinois |
| Stephan Harbarth, MD, MS | Geneva, Switzerland |
| Anthony D. Harris, MD, MPH | Baltimore, Maryland |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | San Juan, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| John A. Jernigan, MD, MS | Atlanta, Georgia |
| Jacob L. Kool, MD, PhD | Fort Collins, Colorado |
| Ebbing Lautenbach, MD, MPH | Philadelphia, Pennsylvania |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Leonard A. Mermel, DO, ScM | Providence, Rhode Island |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Carlene A. Muto, MD, MS | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| David L. Paterson, MBBS, FRACP | Pittsburgh, Pennsylvania |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Yardley, Pennsylvania |
| David A. Pegues, MD | Los Angeles, California |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Jordi Rello, MD, PhD | Tarragona, Spain |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Henning Rüden, MD | Berlin, Germany |
| Lisa Saiman, MD, MPH | New York, New York |
| Syed A. Sattar, PhD | Ottawa, Ontario, Canada |
| William E. Scheckler, MD | Madison, Wisconsin |
| Lynne M. Sehulster, PhD | Atlanta, Georgia |
| Andrew E. Simor, MD | Toronto, Ontario, Canada |
| Denis W. Spelman, FRACP | Melbourne, Victoria, Australia |
| V. Susan Springthorpe, BSc, MSc | Ottawa, Ontario, Canada |
| Jeffrey R. Starke, MD | Houston, Texas |
| Janet E. Stout, PhD | Pittsburgh, Pennsylvania |
| Clyde Thornberry, PhD | Franklin, Tennessee |
| Jerome Tokars, MD, MPH | Atlanta, Georgia |
| Timothy R. Townsend, MD | Baltimore, Maryland |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Sergio B. Wey, MD | São Paulo, Brazil |

SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. (856) 848-1000

**Executive Vice President**

Richard N. Roash

Vice President, Publishing Operations

John C. Carter

Editorial Director

Jennifer Kilpatrick

Executive Editor

Shirley P. Strunk, ELS

Assistant Editor

Jaime Underwood

Circulation Manager

Lester J. Robeson, CCCC

Production Director

Christine Malin

Vice President, U.S. Advertising

Wayne McCourt

Director of Association Services

Kathy Huntley

Advertising Sales Representative

Scotty Turner

Advertising Sales Administrator

Joanne Patterson

Sales Director, Classified/Recruitment


Kristy Irwin

Classified/Recruitment Sales

Elizabeth Roash

Director of Reprint Sales

John Kain



 smith&nephew
ACTICOAT [◇]
with SILCRYST [™]
NANOCRYSTALS

Rapidly kills 150+ types of pathogens for one reason: to reduce the risk of infection

A nosocomial infection increases a patient's medical costs by an average of \$28,800! That's why you need ACTICOAT. The patented Nanocrystalline silver delivery system kills—not just repels—more than 150 clinically relevant wound pathogens. ACTICOAT protects against gram-negative and gram-positive bacteria, and antibiotic-resistant bacteria and fungal organisms, including tough ones such as *Pseudomonas*, Methicillin-resistant *Staphylococcus aureus* (MRSA) and Vancomycin-resistant *Enterococcus* (VRE).


Let ACTICOAT create the ultimate barrier of protection for a healthier wound-healing environment.

To learn more about ACTICOAT, visit www.acticoat.com or call 1-800-876-1261.


1. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of *Staphylococcus aureus* infection in New York City hospitals. *Emerg Infect Dis.* 1999;5:9-17.

No other silver delivery system is faster or more effective than ACTICOAT[®]¹

Vancomycin-resistant *Enterococcus* (VRE) Survival Curves^{1,4}



Methicillin-resistant *Staphylococcus aureus* (MRSA) Survival Curves^{1,4}



Protects against bacteria^{2,3}:

Note: The numbers in parentheses indicate the number of bacteria strains tested.

- Acinetobacter* sp.
- Aeromonas caviae*
- Aeromonas hydrophila*
- Alcaligenes* sp.
- Bacillus cereus* (4)
- Bacillus circulans*
- Bacillus licheniformis* (3)
- Bacillus* sp.
- Bacillus subtilis*
- Branhamella catarrhatis* (2)
- Burkholderia cepacia*
- Citrobacter amalonaticus*
- Citrobacter diversus* (2)
- Citrobacter freundii* (4)
- Citrobacter koseri*
- Corynebacterium minutissimum* (2)
- Enterobacter aerogenes*
- Enterobacter agglomerans* (2)
- Enterobacter cloacae* (7)
- Enterococcus avium* (2)
- Enterococcus durans*
- Enterococcus faecalis* (10) - includes strains of MRSA
- Enterococcus faecium* (4) - includes strains of MRSA
- Enterococcus hirae*
- Enterococcus raffinosus*
- Escherichia coli* (24)
- Escherichia vulnaris*
- Klebsiella orthinolytica*
- Klebsiella oxytoca* (2)
- Klebsiella ozonae* (2)
- Klebsiella pneumoniae* (3)
- Listeria monocytogenes* (7)
- Proteus mirabilis* (2)
- Proteus* sp.
- Proteus vulgaris* (2)
- Providencia alcalifaciens*
- Providencia rettgeri*
- Providencia stuartii* (3)
- Pseudomonas aeruginosa* (15) - includes strains of VRE
- Pseudomonas alcaligenes*
- Pseudomonas cepacia*
- Pseudomonas fluorescens*
- Pseudomonas luteola* (2)
- Pseudomonas* sp.
- Pseudomonas stutzeri* (2)
- Salmonella montevideo*
- Salmonella typhimurium* (2)
- Serratia marcescens*
- Staphylococcus aureus* (12) - includes strains of MRSA
- Staphylococcus epidermidis* (4)
- Staphylococcus haemolyticus* (3)
- Staphylococcus hominis*
- Staphylococcus lugunensis* (3)
- Staphylococcus saprophyticus* (2)
- Staphylococcus schleiferi* (3)
- Staphylococcus xylois*
- Streptococcus mitis*
- Xanthomonas maltophilia* (2)

Broad protection

You can't predict which pathogens may infect wounds at your facility. That's why a silver dressing—ACTICOAT in particular—makes sense. ACTICOAT quickly kills more than 150 pathogens, including gram-negative and gram-positive bacteria, antibiotic-resistant bacteria, and fungal organisms.¹ (See complete list, right.)

Applying ACTICOAT

Follow standard protocol to cleanse the wound; do not use oil-based cleansing agents.

Remove the ACTICOAT dressing from the package and cut to shape.

Dampen the dressing with sterile water or a non-oil based cleansing agent (do not use saline). If heavy exudate is present, a dry dressing may be applied directly to the wound, as the exudate will activate the silver.

Allow the dressing to drain on an absorbent surface for 1-2 minutes.

Apply the ACTICOAT dressing to the wound surface, either side down.

Cover the dressing with an appropriate secondary dressing (consider ALLEVYN[®] exudate management dressings), based on your protocols.

Maintenance

The ACTICOAT dressing should be kept damp, but not so wet as to macerate tissue.

NOTE: Frequency of dressing change is based on clinical judgment and the wound characteristics.

Product Type	Product Code
ACTICOAT 7 Antimicrobial Dressing Delivers an unprecedented 7 days of uninterrupted antimicrobial barrier activity	20141 4" x 5" Dressing 20241 6" x 6" Dressing
ACTICOAT Absorbent Dressing Provides up to 3 days of antimicrobial barrier activity for wounds with moderate to heavy exudates	20181 3/4" x 12" Rope 20381 4" x 5" Dressing
ACTICOAT Burn Dressing With proprietary antimicrobial silver nanocrystals. Provides 3 days of unsurpassed, fast-acting, long-lasting antimicrobial barrier control.	20101 4" x 4" Dressing 20201 4" x 8" Dressing 20301 8" x 16" Dressing 20401 16" x 16" Dressing 20501 4" x 48" Roll

To learn more about ACTICOAT, visit www.acticoat.com or call 1-800-876-1261.

[®]Trademark of Smith & Nephew. Certain marks reg. US Pat & TM Off.

[™] SILCRYST is a trademark of NUCRYST Pharmaceutical Corp., used under license.

All trademarks acknowledged.

© 2004 Smith & Nephew

Protects against yeasts & molds:

- Candida glabrata*
- Candida albicans*
- Candida tropicalis*
- Saccharomyces cerevisiae*
- Aspergillus fumigatus*

1. Data on file: Testing performed by Hoosier Microbiological Laboratory, Muncie, IN (independent lab), Oct. 2003.

2. Data on file: Scientific Background #0109003 and #0107010.

3. Wright, JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. *Am J Infect Control*. 1999;27:344-350.

4. Data on file for ACTICOAT Burn: Scientific Background #0107011, #21 and #22, and #0109005.

5-way infection control in one complete system

Only the Bardex[®] I.C. Complete Care[™] Infection Control Foley Catheter* System including Bacti-Guard[®]* silver alloy coating^{1,2,3} offers complete infection control to address the 5 risk areas during catheterization.

1 Reduce risks while catheter is indwelling^{1,2,3}

2 Minimizes infection risk at the catheter-tubing junction

3 Repels bacteria and yeasts during drainage

4 Protects against retrograde bacterial migration at the outlet



Now with the new Bard EZ-Lok[™] Sampling Port

5 Resists pathogen colonization at collection

Find out more about the Bardex[®] I.C. Complete Care[™] Infection Control Foley Catheter* System.

Call 800-526-4455.

1. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. *Emer Infect Dis.* 2001;7:342-347.
2. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Arch Int Med.* 2000;160:3294-3298.
3. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. *Arch Int Med.* 2000;160:2670-2675.

Please consult product label and insert for any indications, contraindications, hazards, warnings, cautions and directions for use. *The Foley catheters included in the Bardex I.C. Complete Care System contain Bacti-Guard[®] silver alloy coating, which is licensed from Adhesive Technology (International) Licensing, B.V. Bard and Bardex are registered trademarks of C.R. Bard, Inc., or an affiliate. The I.C. logo and Complete Care are trademarks of C.R. Bard, Inc., or an affiliate. Bacti-Guard is a registered trademark of Adhesive Technology (International) Licensing, B.V. ©2004 C.R. Bard, Inc. All Rights Reserved.



FACULTY SEARCH

Department of Internal Medicine
Division of Infectious Diseases
The Ohio State University

The Division of Infectious Diseases has an opening for an Assistant or Associate Professor in the area of Hospital Epidemiology and Infection Control. Candidates should have an MD, MD/MPH, or MD/PhD. The individual will be responsible for development of an antimicrobial management program for the OSU Hospitals, consisting of OSU, James Cancer, University Hospitals East and the soon to be opened Richard M. Ross Heart Hospital. Board Certification in IM, board eligibility/certification in ID and an interest in antimicrobial resistance mechanisms are desirable. The individual will work closely with the Epidemiology and Pharmacy Departments to achieve their goals. The position provides potential to perform research related to Hospital Infection Control.

Applications should include a curriculum vitae, description of research experience, and a list of three references. Information about the University can be obtained by contacting our web site (<http://www.osu.edu>)

Send application to:

Larry Schlesinger, M.D.

**Director, Division of Infectious Diseases
410 W. 10th Avenue, Room N-1147 Doan Hall
Columbus, OH 43210**

The Ohio State University is an Equal Opportunity/Affirmative Action Employer. Qualified women, minorities, Vietnam-era veterans and individuals with disabilities are encouraged to apply.



**Our Kids Would
Like To Meet You!**

Infection Control Nurse

Kosair Children's Hospital is seeking an experienced Infection Control Practitioner to coordinate and implement our infection control and surveillance program. Duties include policy development and review, data analysis, outbreak investigation and collaboration on construction projects.

- *MSN required*
- *Certificate in Infection Control*
- *Minimum 3 years of Clinical Nursing experience*
- *Minimum 2 years of Infection Control experience*
- *Excellent written and oral communication skills*
- *Experience developing and delivering educational programs related to infection control*
- *Training in epidemiology and familiarity with research preferred*

Norton Healthcare, the largest health care system in Kentucky, offers a competitive salary and complete benefits package including a 403(b). And when you're not working you'll enjoy Louisville's vibrant and affordable Midwestern lifestyle, with lots of cultural and recreational alternatives.

For more information,
call Toni Haysley:

(800) 833-7975 or
(502) 629-2965

Fax: **(502) 629-3695**

Email:
toni.haysley@nortonhealthcare.org



**KOSAIR
CHILDREN'S
HOSPITAL**

A Part of Norton Healthcare

www.careers.nortonhealthcare.com

EOE M/F/D/V



Infectious Disease

Allegheny General Hospital is recruiting an individual for a full-time position in Infectious Diseases. Primary responsibilities will be in Infection Control and Hospital Epidemiology. Prior experience in this area is preferred. Other responsibilities will encompass inpatient and outpatient consultive infectious disease practice, including HIV medicine at our Ryan White funded HIV/AIDS clinic. A strong commitment to the clinical teaching of medical students and residents is required. Academic rank will be based on qualifications, with a faculty appointment with the Drexel University College of Medicine. Applicants must be board certified or board eligible in Infectious Diseases.

Please send your CV and cover letter to:

**Richard P. Shannon, MD, Chairman
Department of Medicine**

**ALLEGHENY GENERAL HOSPITAL
320 East North Avenue, Pittsburgh, PA, 15121 or
Email: rshannon@wpahs.org**

Without the right
infection prevention system,
you may as well
operate in the

WAITING ROOM



Introducing 3M Infection Prevention Solutions.

Every step in the infection prevention process is critical, or your operating room could be as contaminated as the common areas. But who can keep up with all of the new products and research developments available today? We can.

At 3M, we are committed to helping health care facilities reduce the risk of nosocomial infections. So we not only

provide you with innovative products – we equip you with a comprehensive *system* of products, services and technical support, as well as educational and in-service programs all customized for your hospital.

For more information, call the 3M Health Care Customer Helpline at **1-800-228-3957** or click on www.3M.com/healthcare. We're with you, step by step.

3M Infection Prevention Solutions. A vital step in Infection Prevention.

© 3M 2004 TM-0185

3M Medical

from the 3M Health Care family

3M